MediGene AG Spins Out mTCR Program - Independent Company Immunocore Limited Founded

Published: Oct 01, 2008

Martinsried/Munich, October 1, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) and three private investors have founded Immunocore Ltd, which will focus on the technology platform for monoclonal T-cell receptors (mTCR) of MediGene's UK subsidiary MediGene Ltd. MediGene holds a 38.5% stake in Immunocore Ltd and will be the largest shareholder of the new company.

The further development of the mTCR technology will be fully financed by Immunocore Ltd. MediGene is free from any financial obligations as of 1st October 2008. In addition, MediGene has retained the right of first refusal for defined cancer indications for further development. This spin-out is part of the continued focusing of MediGene's business and will significantly reduce the company's cash burn.

MediGene Ltd. was based on the 2006 acquisition of the UK biotech company Avidex Ltd and will be retained as a subsidiary. MediGene will retain the MediGene Ltd's lead product, RhuDex®, for the treatment of rheumatoid arthritis and a second programme in preclinical development.

On October 1, 2008, Immunocore Ltd will take over the employees of MediGene Ltd as well as the company's offices and lab space in Oxfordshire, UK. James Noble, previously the Chief Executive Officer of Avidex Ltd and a former member of MediGene AG's Supervisory Board, will be the Chief Executive Officer of the new company. Dr Peter Heinrich, Chief Executive Officer of MediGene AG, will become a member of Immunocore's Board of Directors.

Dr Peter Heinrich, Chief Executive Officer of MediGene AG, commented: "We are very pleased to have laid the foundation for the continuation and acceleration of the mTCR programme with this spin-out of Immunocore Ltd. As a shareholder, MediGene will benefit from Immunocore's potential upside, while at the same time MediGene expects significant cost reductions and a strengthened focus of its business model. Our clinical programmes in oncology and autoimmune diseases will be our future core activities."

In June 2008, MediGene announced its intention to focus its business activities following positive clinical data on its drug candidate EndoTAG(TM)-1 for the treatment of pancreatic cancer, and that its future activities will be based on programs in oncology and immunology. The company's key R&D programs will be EndoTAG(TM)-1 and RhuDex®. As part of this focus, in August 2008, MediGene sold the European rights to its dermatology treatment Oracea® to the pharmaceutical company Galderma. This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. EndoTAG(TM) and MediGene® are registered trademarks of MediGene AG. RhuDex® is a registered trademark of MediGene Ltd. These trademarks may be owned or licensed in select locations only.

MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies. MediGene has several drug candidates in clinical development, some of which providing a substantial sales potential. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treatment of cancer and autoimmune diseases.

Contact MediGene AG E-mail: Fax:++49 - 89 - 85 65 - 2920 Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 - 85 65 - 3324 Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946

Contact Immunocore Limited James Noble, Tel.: ++44-1235 438600

Back to news